Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

In-time TReatment of acUte ischaemic STroke

Project description

Fast response for stroke patients

Across Europe, only about 30 % of acute ischaemic stroke (AIS) patients receive specialised and timely care, and few hospitals have stroke radiologists on staff. Optimal treatment of a patient is only possible in only 5 % of hospitals. Stepping in to provide high-resolution imaging based on benchmarks and the patient’s own data, iTrust uses Convolutional Neural Networks to provide medical staff with immediate data like stroke lesion segmentation and volume estimations. The expected wide distribution of the software, which also reduces routine manual work, will be based on an annual licensing fee and on strategic partnerships with major CT and MRI vendors.

Objective

The problem: Today the complex and time-critical therapeutic decision in Acute Ischaemic Stroke (AIS) relies on the availability of expert stroke radiologists. However, only 5% of hospitals have facilities meeting the standards of comprehensive stroke centres. Thus, for 95% of hospitals, optimal treatment cannot be quickly identified and safely commenced. Consequently, only about 30% of AIS patients receive specialized stroke unit care across Europe.

The solution: iTrust is a clinical decision support (CDS) software that uses Convolutional Neural Networks to predict the outcome of treatment strategies in AIS, based on the patient’s biomarkers as well as clinical information, including brain scan images. The prediction shown as high-resolution images of probable brain tissue outcomes in function of each treatment available.

The market: Revenue from the iTrust software will come as annual licences fees: a model clearly preferred according to the surveyed KOLs. Initially, the distribution of the software will be carried out through strategic partnerships (formal agreements already signed) with the major medical scanner (CT, MRI) vendors, which will allow us to exploit their global sale channels and large installed base. The total addresable market for iTrust is over EUR 430 million per year in OECD countries. Given the high incidence of AIS, low volume (5%) of hospitals prepared to initiate the treatment and the high importance of quickly allocating the appropriate therapeutic intervention, we estimate an accumulated turnover exceeding EUR 41 million of the iTrust solution, five years post-project.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME - SME instrument

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

CERCARE MEDICAL APS
Net EU contribution
€ 1 831 375,00
Address
INGE LEHMANNS GADE 10
8000 Aarhus C
Denmark
SME
Yes
Region
Danmark Midtjylland Østjylland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 2 616 250,00